Can Ono Pharmaceutical bring clearer treatment sequencing to advanced GIST in Japan?
Ono Pharmaceutical has filed ripretinib in Japan for advanced GIST. Read why the move could reshape late-line treatment access and sequencing.
Why Merck and Eisai’s belzutifan–lenvatinib combo could reset treatment sequencing in advanced renal cell carcinoma
Belzutifan plus lenvatinib outperforms cabozantinib in Phase 3 renal cell carcinoma data. Find out what this changes for post-immunotherapy care.
Gossamer Bio Phase 3 PROSERA results: what seralutinib’s near miss means for pulmonary arterial hypertension
Gossamer Bio’s Phase 3 PROSERA data for seralutinib in PAH missed its primary endpoint. Read what this means for regulators and clinicians.